DOI QR코드

DOI QR Code

Sperm-Associated Antigen 9 is a Promising marker for Early Diagnosis of Endometrial Cancer

  • Baser, Eralp (Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital) ;
  • Togrul, Cihan (Department of Obstetrics and Gynecology, Diyarbakir Women's and Children's Hospital) ;
  • Ozgu, Emre (Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital) ;
  • Ayhan, Sevgi (Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital) ;
  • Caglar, Mete (Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital) ;
  • Erkaya, Salim (Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital) ;
  • Gungor, Tayfun (Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Education and Research Hospital)
  • Published : 2013.12.31

Abstract

Background: Sperm-associated antigen 9 (SPAG9) has been recently proposed as a novel biomarker for early diagnosis of several human tumors, including ovarian, cervical and breast cancers. Its clinical value remains to be clarified for endometrial cancer (EC). In this study, we investigated the utility of serum SPAG9 levels in diagnosis of EC and its association with important clinicopathological parameters. Materials and Methods: This cross-sectional study was performed at a tertiary women's referral center in Ankara, Turkey. Preoperative serum samples were collected from patients surgically treated for endometrial cancer between June 2012-April 2013. Similar aged women with a biopsy proven benign endometrium were used as controls. Serum SPAG9 levels were measured with an enzyme-linked immunosorbent assay (ELISA) method and assessed for links with clinicopathological factors. Receiver operating characteristic (ROC) curve analysis was performed to assess power of SPAG9 levels for EC prediction. P values less than 0.05 were considered statistically significant. Results: A total of 63 women with EC and 27 with benign endometrium were included in the study. Mean age in the EC group was $58.7{\pm}1.1$. Median SPAG9 levels in the EC and control groups were 18.3 (range, 12.7-53.8) and 14.1 (range, 4.3-65.3), respectively (p<0.001). A cut-off value of 17 ng/ml for SPAG9 predicted presence of malignant endometrium with 74% sensitivity and 83% specificity [Area under curve (AUC)=0.82, p<0.001]. SPAG9 levels did not demonstrate any significant association with histological type, FIGO stage, tumor grade, size, myometrial invasion, lymphovascular space invasion, cervical involvement, adnexal involvement, peritoneal cytology or lymph node status (all p>0.05). Conclusions: Testing for SPAG9 may be useful for early detection of EC in asymptomatic high-risk women. Its role in post-treatment follow-up and early detection of recurrence should be assessed in future trials.

References

  1. Chung HH, Kim JW, Park NH, et al (2006). Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand, 85, 1501-5. https://doi.org/10.1080/00016340601022777
  2. Garg M, Chaurasiya D, Rana R, et al (2007). Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res, 13, 1421-8. https://doi.org/10.1158/1078-0432.CCR-06-2340
  3. Garg M, Kanojia D, Khosla A, et al (2008). Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res, 68, 8240-8. https://doi.org/10.1158/0008-5472.CAN-08-1708
  4. Garg M, Kanojia D, Salhan S, et al (2009a). Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer, 115, 2671-83. https://doi.org/10.1002/cncr.24293
  5. Garg, M, Kanojia D, Suri S, et al (2009b). Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab, 94, 4613-8. https://doi.org/10.1210/jc.2009-0703
  6. Jagadish N, Rana R, Mishra D, et al (2005a). Sperm associated antigen 9 (SPAG9): a new member of c-Jun NH2 -terminal kinase (JNK) interacting protein exclusively expressed in testis. Keio J Med, 54, 66-71. https://doi.org/10.2302/kjm.54.66
  7. Jagadish N, Rana R, Selvi R, et al (2005b). Characterization of a novel human sperm-associated antigen 9 (SPAG9) having structural homology with c-Jun N-terminal kinaseinteracting protein. Biochem J, 389, 73-82. https://doi.org/10.1042/BJ20041577
  8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  9. Kanojia D, Garg M, Gupta S, et al (2009). Sperm-associated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev, 18, 630-9. https://doi.org/10.1158/1055-9965.EPI-08-0629
  10. Kanojia D, Garg M, Gupta S, et al (2011). Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol, 178, 1009-20. https://doi.org/10.1016/j.ajpath.2010.11.047
  11. Pecorelli S (2009). Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet, 105, 103-4. https://doi.org/10.1016/j.ijgo.2009.02.012
  12. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36. https://doi.org/10.3322/caac.20121
  13. Suri A (2006). Cancer testis antigens--their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther, 6, 379-89. https://doi.org/10.1517/14712598.6.4.379
  14. Wang Y, Dong Q, Miao Y, et al (2013). Clinical significance and biological roles of SPAG9 overexpression in non-small cell lung cancer. Lung Cancer, 81, 266-72. https://doi.org/10.1016/j.lungcan.2013.04.021
  15. Yi F, Ni W, Liu W, et al (2013). SPAG9 is overexpressed in human astrocytoma and promotes cell proliferation and invasion. Tumour Biol, 34, 2849-55. https://doi.org/10.1007/s13277-013-0845-5
  16. Yildiz A, Yetimalar H, Kasap B, et al (2012). Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol, 164, 191-5. https://doi.org/10.1016/j.ejogrb.2012.05.038
  17. Yu P, Yan L, Zhang H, et al (2012). Expression and clinical significance of sperm-associated antigen 9 in patients with endometrial carcinoma. Int J Gynecol Cancer, 22, 87-93. https://doi.org/10.1097/IGC.0b013e3182370f2e

Cited by

  1. Lack of Relation of Survivin Gene Expression with Survival and Surgical Prognostic Factors in Endometrial Carcinoma Patients vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6905
  2. Antibody Immobilization Method for Immonosensor Application vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5115
  3. Accuracy of Sentinel Node in Detecting Lymph Node Metastasis in Primary Endometrial Carcinoma vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6691
  4. Discovery of biomarkers for endometrial cancer: current status and prospects vol.16, pp.12, 2016, https://doi.org/10.1080/14737159.2016.1258302
  5. Cancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancer vol.35, pp.5, 2016, https://doi.org/10.3892/or.2016.4645